Last reviewed · How we verify
PF-06821497 Treatment B (pf-06821497-treatment-b)
PF-06821497 Treatment B (generic name: pf-06821497-treatment-b) is a drug developed by Pfizer Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | pf-06821497-treatment-b |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Vessel puncture site bruise
- Nail avulsion
- Neck pain
- Disturbance in attention
- Eyelid pain
- abdominal discomfort
- Abdominal pain
- Constipation
- Nausea
- Vessel puncture site pain
- Fall
Key clinical trials
- A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). (PHASE3)
- A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants. (PHASE1)
- A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06821497 Treatment B CI brief — competitive landscape report
- PF-06821497 Treatment B updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about PF-06821497 Treatment B
What is PF-06821497 Treatment B?
PF-06821497 Treatment B (pf-06821497-treatment-b) is a pharmaceutical drug developed by Pfizer Inc..
Who makes PF-06821497 Treatment B?
PF-06821497 Treatment B is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of PF-06821497 Treatment B?
pf-06821497-treatment-b is the generic (nonproprietary) name of PF-06821497 Treatment B.
What development phase is PF-06821497 Treatment B in?
PF-06821497 Treatment B is in Phase 1.
What are the side effects of PF-06821497 Treatment B?
Common side effects of PF-06821497 Treatment B include Headache, Vessel puncture site bruise, Nail avulsion, Neck pain, Disturbance in attention, Eyelid pain.
Related
- Manufacturer: Pfizer Inc. — full pipeline
- Compare: PF-06821497 Treatment B vs similar drugs
- Pricing: PF-06821497 Treatment B cost, discount & access